Sonrgy Inc. made two key appointments, including naming Brian O’Callaghan the company’s chairman and CEO.
Sonrgy, a San Diego-based biotech company developing focused drug delivery technologies, also appointed David Renas as chief financial officer.
O’Callaghan was most recently the CEO at Sangart Inc., a San Diego-based pharmaceutical company. He brings 25 years of senior management experience in the life science sector, with companies that include NPS Pharmaceuticals; Covance; Novartis; BioPartners, where he was a co-founder; Merck; Pfizer; and Bayer, according to Sonrgy.
Renas is also a former executive of Sangart, where he was CFO and general counsel.
Sonrgy said these appointments are aimed at helping the company develop its first clinical drug candidate using Sonrgy’s proprietary SonRx delivery platform. Sonrgy is using ultrasound as part of its targeted delivery system for fighting cancer and other diseases.
“I am delighted to join Sonrgy. This is a very promising technology with a real opportunity to address the need for precise drug delivery, particularly in the oncology space,” O’Callaghan said.